Aus Bio Ltd. is a public but unlisted, Melbourne based biotechnology company.
Aus Bio’s current research and management philosophy is to focus on identifying chronic disease states where:
- large markets exist
- new and improved treatments are required.
To this end, the company is current developing:
- Wound Healing for Chronic Wounds and Lower Limb Venous Ulceration
- Treatments for the Management of Diabetes Mellitus and Insulin Resistance
- Novel pharmaceuticals for the Treatment of Hepatitis B and C and the Development of a Bioassay
- Pharmaceuticals for Specific Acute and Chronic Respiratory Conditions
- Novel pharmaceuticals and synergistic compounds as non antibiotic feed additives for the Poultry and Swine Industry
The Wound Healing Compounds project is the most advanced of the Company’s R & D. A Phase I (Safety) Clinical Study was completed during May, 2006 in subjects with chronic venous ulcers. Subject to regulatory approval it is now planned to commence Phase IIb/III study during Q1/Q2, 2008. Fifteen to 20 recruitment sites will be involved in the recruitment of 160 subjects.
Clinical Trial Title: A Phase IIb/III, Randomised, Multi Centre Study to Evaluate the Efficacy and Safety of MD 920 (Gibberellic Acid and Salt 1:1) Adsorbed to a Non Adhesive Dressing Used with Standard 4 Layered Compression Therapy Compared with Standard 4 Layered Compression Therapy alone in Patients with Hard to Heal Chronic Venous Ulceration.